It seems that Australia suits Chloé Dygert, with the Canyon-SRAM zondacrypto rider cheerfully rocking up to another podium, ...
Patients who receive kidney transplants from Epstein–Barr virus D-positive/R-negative donors face a higher risk of ...
Multiple sclerosis (MS) is a progressive autoimmune disease that affects the brain and spinal cord, impacting 2.8 million ...
A randomized crossover trial found minimal difference between blood pressure (BP) readings obtained in public spaces versus those taken in private offices.
In this retrospective cohort study, individuals who were Epstein-Barr virus-seronegative had higher rates of post-transplant ...
A study suggests that catching COVID-19 significantly raises the risk of developing ME/CFS (formerly called "chronic fatigue ...
The following is a summary of “Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection ...
The FDA placed a clinical hold on two Atara assets, following an inspection at a third-party site that also led to a CRL for ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.
Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND, ...
Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback